Dr. David Golombos, MD
Claim this profileStony Brook Cancer Center
Studies Bladder Cancer
Studies Cancer
2 reported clinical trials
2 drugs studied
Area of expertise
1Bladder Cancer
Stage II
Stage I
2Cancer
Stage II
Stage I
Affiliated Hospitals
Stony Brook Cancer Center
More about David Golombos, MD
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 0 Active Clinical TrialsTreatments David Golombos, MD has experience with
- UGN-102
- TURBT
Breakdown of trials David Golombos, MD has run
Bladder Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Golombos, MD specialize in?
David Golombos, MD focuses on Bladder Cancer and Cancer. In particular, much of their work with Bladder Cancer has involved Stage II patients, or patients who are Stage I.
Is David Golombos, MD currently recruiting for clinical trials?
No, David Golombos, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that David Golombos, MD has studied deeply?
Yes, David Golombos, MD has studied treatments such as UGN-102, TURBT.
What is the best way to schedule an appointment with David Golombos, MD?
Apply for one of the trials that David Golombos, MD is conducting.
What is the office address of David Golombos, MD?
The office of David Golombos, MD is located at: Stony Brook Cancer Center, Stony Brook, New York 11794 United States. This is the address for their practice at the Stony Brook Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.